Difference between revisions of "Malignant peritoneal mesothelioma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://www.ncbi.nlm.nih.gov/pubmed/" to "https://pubmed.ncbi.nlm.nih.gov/") |
Warner-admin (talk | contribs) m (Text replacement - "#eeeeee" to "#82a4ff") |
||
(3 intermediate revisions by the same user not shown) | |||
Line 21: | Line 21: | ||
=Advanced or metastatic disease, subsequent lines of therapy= | =Advanced or metastatic disease, subsequent lines of therapy= | ||
==Atezolizumab & Bevacizumab {{#subobject:8ahgy7|Regimen=1}}== | ==Atezolizumab & Bevacizumab {{#subobject:8ahgy7|Regimen=1}}== | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#82a4ff"> |
===Regimen {{#subobject:6d0c87|Variant=1}}=== | ===Regimen {{#subobject:6d0c87|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
Line 33: | Line 33: | ||
|- | |- | ||
|} | |} | ||
− | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#f2f3f4"> |
====Immunotherapy==== | ====Immunotherapy==== | ||
*[[Atezolizumab (Tecentriq)]] 1200 mg IV once on day 1 | *[[Atezolizumab (Tecentriq)]] 1200 mg IV once on day 1 | ||
Line 41: | Line 41: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''MDACC 2016-0861:''' Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. [https://doi.org/10.1158/2159-8290.cd-21-0331 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8563380/ link to PMC article] ''' | + | #'''MDACC 2016-0861:''' Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. [https://doi.org/10.1158/2159-8290.cd-21-0331 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8563380/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34261675/ PubMed] [https://clinicaltrials.gov/study/NCT03074513 NCT03074513] |
[[Category:Malignant peritoneal mesothelioma regimens]] | [[Category:Malignant peritoneal mesothelioma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Gastrointestinal cancers]] | [[Category:Gastrointestinal cancers]] | ||
[[Category:Mesotheliomas]] | [[Category:Mesotheliomas]] |
Latest revision as of 12:53, 31 July 2024
Section editor | |
---|---|
Marjorie G. Zauderer, MD, MS, FACP Memorial Sloan Kettering Cancer Center New York, NY, USA |
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
EURACAN/PSOGI
- 2020: Kusamura et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up PubMed
NCCN
Advanced or metastatic disease, subsequent lines of therapy
Atezolizumab & Bevacizumab
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Raghav et al. 2021 (MDACC 2016-0861) | 2017-2019 | Phase 2 |
Immunotherapy
- Atezolizumab (Tecentriq) 1200 mg IV once on day 1
Targeted therapy
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles
References
- MDACC 2016-0861: Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT03074513